SELLAS Life Sciences Stock Falls 17% After Announcement Of Phase 3 REGAL Trial Milestone

SELLAS Life Sciences (SLS) shares dropped after the company announced its Phase 3 REGAL trial reached a key milestone, requiring a final analysis before a topline readout. The trial's progress is a critical development for investors.

Sellas Life Sciences' stock fell 18% after announcing its Phase 3 REGAL trial in acute myeloid leukemia reached the 80th death, triggering final analysis. The trial took longer than expected, and topline results are due this quarter. Sellas had $138 million in cash at June 30. According to the CEO, a successful trial could lead to an FDA filing.

SELLAS Life Sciences (NASDAQ:SLS) announced its Phase 3 REGAL trial for galinpepimut-S in AML patients reached the 80th event, triggering final analysis. The company plans to release topline results this quarter. Galinpepimut-S targets the WT1 protein and is being evaluated for maintenance therapy in AML. SELLAS also develops SLS009, a CDK9 inhibitor for AML.

SELLAS Life Sciences (SLS) completed its Phase 3 REGAL AML trial after reaching 80 deaths, triggering final analysis. The company expects to report preliminary results this quarter. The milestone reduces timing uncertainty for the trial's outcome.

SELLAS Life Sciences (SLS) announced its Phase 3 REGAL trial for galinpepimut-S (GPS) in AML patients reached 80 deaths, triggering final analysis. Results are expected this quarter. GPS targets WT1 protein in various cancers. The company also develops SLS009, a CDK9 inhibitor for AML.

SELLAS Life Sciences (SLS) is approaching the 80-death event trigger for its Phase 3 REGAL trial and continues enrollment in the Phase 2 SLS009 trial, with initial data expected in Q4. The stock rose 7% to $12.31, ending a three-quarter decline, as traders noted its HQ lease and upcoming milestones.